Sartorius Stedim Biotech, a specialist technology partner in the biopharmaceutical industry, has been selected by ABL Europe to be its primary supplier of single-use systems.
ABL Europe, a subsidiary of ABL, provides dedicated viral vector good manufacturing practice (GMP) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch.
Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg.
Sartorius Stedim Biotech has delivered a comprehensive GMP viral vector manufacturing solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration and mixing. These have been installed at the facility, which is now in the process of manufacturing batches of viral vector products for ABL’s clients.
Sartorius Stedim Biotech’s process solutions in single-use (SU) format have helped ABL expand its existing drug substance capacity, with a fully disposable manufacturing capability for different viral vector product types produced in non-adherent cell lines.
Patrick Mahieux, General Manager of ABL Europe, said: “The introduction of non-adherent cell culture capacity complements our existing adherent cell culture viral vector production technologies."
He continued: "It is the only pure-play, dedicated viral vector production site capable of manufacturing drug substance and drug product materials for toxicological studies, all clinical phases and even commercial launch. Everything from process development, manufacturing and QC release testing is performed under one roof.”
